Diabetologia 48 , 578585 (2005)
Weight variability and diabetes complications
Sun L, Yao SY, Zuo ZF, et al
What we monitor: What we monitor: What we monitor: What we monitor: What we monitor: What we monitor: What we monitor: What we monitor: YOUR PERSONALIZED PLAN Science-backed strategies to protect your health and extend your quality of life

Introduction Molecular Biology of DPP4 Discovery, genomic organization, and superfamily of related enzymes Molecular function Regulation of DPP4 expression Post-translational modifications of DPP4 DPP4 Substrates Brain natriuretic peptide (BNP) Erythropoietin Eotaxin Gastrin-releasing peptide (GRP) Glucagon Glucagon-like peptide-1 (GLP-1) Glucagon-like peptide-2 (GLP-2) Glucose-dependent insulinotropic polypeptide (GIP) Granulocyte colony-stimulating factor (G-CSF) Granulocyte-macrophage CSF (GM-CSF) GHRH and IGF-1 High-mobility group box 1 (HMGB1) Macrophage-derived chemokine (MDC) Macrophage inflammatory protein-1 (MIP-1 ), chemokine (C-C motif) ligand 3-like 1 (CCL3L1), or LD78 Oxyntomodulin Pituitary adenylate cyclase-activating polypeptide (PACAP) Neuropeptide Y (NPY) Peptide tyrosine tyrosine (PYY) Regulated on activation, normal T cell expressed and secreted (Rantes) Stromal cell-derived factor-1 (SDF-1) Substance P (SP) Discovery of DPP4 as a Drug Target Selective DPP4 inhibitors, glucoregulatory substrates, and the treatment of type 2 diabetes Metabolic phenotypes in animal models of DPP4 deficiency Mechanism(s) of Action of DPP4 Inhibitors Selectivity of DPP4 inhibitors Mechanisms through which DPP4 inhibitors lower glucose Proof of concept and mechanisms for DPP4-dependent glucose control in humans Role of DPP4 in Endocrine Pathophysiology Adipose tissue Cardiovascular system Autoimmune disorders and inflammation Miscellaneous metabolic actions of DPP4 inhibitors Summary and Future Directions I

Resveratrol treatment in patients with polycystic ovary syndrome decreased pro-inflammatory and endoplasmic reticulum stress markers